Research on the trials that test new treatments in patients. Covers trial design, respiratory and cancer trials, screening tools, and treatment breakthroughs.
The article reviews additive manufacturing technology for biomedical metals, enabling customized implants with precise internal structures. It highlights the integration of AI and 4D printing, addressing challenges in production costs, regulatory compliance, and post-processing.
New UCLA-led research finds that Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults. The study suggests that Paxlovid's potential effect on COVID-19 hospitalization in vaccinated older adults is four times weaker than originally reported.
A new mobile health app-based intervention, BEST-U, is expanding to train non-mental health professionals in delivering the treatment. The 11-week program has shown 'most participants were fully recovered from their eating disorder' at the University of Kansas.
A recent Lancet article revealed that durvalumab combined with radiation therapy offers no benefits for patients with head and neck cancer who cannot receive cisplatin. However, a new clinical trial is underway to test the use of a heavy metal to enhance radiation therapy, providing potential new options for these patients.
A long-term study found that Roux-en-Y gastric bypass outperforms sleeve gastrectomy in treating obesity, with patients losing more excess body mass index. The Swiss Multicenter Bypass or Sleeve Study demonstrated the superiority of Roux-en-Y gastric bypass over sleeve gastrectomy for patient weight loss.
Groundbreaking research from the CLEAR study reveals that greater tumor shrinkage improves survival outcomes for patients with advanced renal cell carcinoma. The lenvatinib and pembrolizumab combination regimen demonstrates significant long-term benefits, including enhanced effectiveness of subsequent treatments.
Researchers are testing noninvasive electrical stimulation of the spinal cord to treat major depressive disorder. The trial, funded by the National Institute of Mental Health, aims to confirm whether this method reduces signaling in specific pathways related to depression.
Researchers found that radiation combined with immune checkpoint inhibitors durvalumab and tremelimumab resulted in durable responses allowing for bladder preservation in localized MIBC patients. The study showed a high efficacy rate of 93% complete response rate, with 84% overall survival rate after two years.
Researchers analyzed data from three trials and found nerinetide provided a clinically significant benefit to patients. The findings suggest that treating early, fast, and administering the drug can lead to improved patient outcomes.
Researchers at Mass General Brigham used a generative AI tool to screen patients for a heart failure clinical trial, significantly improving speed and efficiency compared to manual screening. The study found that the AI-assisted screening process screened 458 eligible patients compared to 284 in the manual group.
A new clinical trial will evaluate whether adding ketamine to standard treatment can improve outcomes for patients suffering from status epilepticus. The trial, called KESETT, hopes to determine whether ketamine can terminate the seizures in more patients than current treatments.
Researchers found that olpasiran significantly lowers lipoprotein(a) levels by over 95% and reduces oxidized phospholipids, which promote atherosclerosis. The study also showed no significant effects on inflammatory markers.
A single-dose breakthrough: PfSPZ-LARC vaccines offer high-level protection against malaria. By leveraging genetic engineering, the vaccine harnesses weakened parasites that replicate in the liver but halt progression to the blood stage.
A new mechanical heart pump, BrioVAD, is being tested against the current standard, HeartMate 3, in a national study. The trial aims to enroll 780 participants with advanced heart failure and will compare the two devices head-to-head.
Researchers at TUM have developed a new therapeutic approach combining dietary therapy with fecal microbiome transfer to sustain inflammation-free states in Crohn's disease patients. The study found that the gut microbiome changes as a result of dietary therapy contribute to treatment success.
A new clinical trial at UVA is testing an innovative AI-powered device designed to improve automated insulin delivery, aiming to simplify diabetes management. The trial will evaluate the 'Bolus Priming System with Reinforcement Learning' technology in adult participants with Type 1 Diabetes.
Researchers at MD Anderson Cancer Center have made significant advancements in treating oligometastatic prostate cancer, advanced urothelial cancer, and triple-negative breast cancer. Personalized risk-based screening is also being explored as a tool to reduce cancer deaths.
Researchers report that eating increasingly higher doses of peanut butter enabled 100% of children with peanut allergy who initially tolerated half a peanut to consume three tablespoons without an allergic reaction. The therapy could potentially fulfill an unmet need for about half of children with peanut allergy, who already can toler...
UCalgary researchers confirm that endovascular thrombectomy (EVT) is not effective for patients with blockages in medium-sized blood vessels. The ESCAPE-MeVO clinical trial found no improvement in outcomes for these patients compared to standard care. EVT was previously shown to improve patient outcomes after large-vessel strokes.
A new drug-free intervention targets the root cause of progressive loss of neural function in SMA by gradually reawakening functionally silent motor neurons. Early results show improved leg muscle strength and walking in adults with SMA, regardless of symptom severity.
Researchers at the University of Cincinnati presented studies on intracerebral hemorrhage treatment eligibility, finding only 3% of patients are eligible for a minimally invasive procedure. Additionally, a study found racial disparities in stroke recovery, with Black individuals experiencing worse functional outcomes after ischemic str...
A phase 1 trial of a personalized cancer vaccine for patients with stage III or IV clear cell renal cell carcinoma showed a positive response in all nine patients, with no higher-grade side effects reported. The vaccine generated a successful anti-cancer immune response and kept patients cancer-free at the time of data cut-off.
A cluster trial found salt substitution to be safe, with significant reductions in stroke recurrence and death rates among patients. The study supports large-scale implementation of this low-cost intervention as a major public health gain.
A study from the University of Gothenburg found that testosterone increases damage following a heart attack by increasing white blood cell release from bone marrow. This affects both men and women, but has a greater impact on male hearts.
A $10.8 million trial will enroll 600 patients aged 60+ to determine whether a hip replacement or internal fixation surgery is better for certain types of hip fractures. The study's patient-focused approach aims to inform clinical guidelines and help patients make informed decisions about their care.
Researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a chronic inflammatory skin condition. The treatment, baricitinib, selectively blocks specific inflammatory pathways, reducing inflammation and suppressing the overactive immune response that contributes to the disease.
A new study adds weight to the safety and effectiveness of a gene therapy for hypophosphatasia, a rare inherited disorder that causes abnormal bone development. The treatment, AAV8-TNAP-D10, has shown promising results in mice models, with female mice achieving improvements in bone and teeth at lower doses.
A new study published in The Lancet Digital Health found that AI-supported breast cancer screening increased the detection of early-stage invasive cancers by 24% compared to traditional screening. AI also identified pre-cancerous lesions with a 51% higher rate, without increasing false positives.
A new study from the University of Birmingham found that digoxin is more effective than beta-blockers in reducing adverse events and hospital admissions for older patients with atrial fibrillation. This could lead to significant cost savings for the UK National Health Service, estimated at £102 million per year.
The NIH-funded clinical trial aims to evaluate the safety and ability of AV-1 to lessen symptoms in people suffering from dengue. The study will expose adult volunteers to a weakened strain of dengue virus and administer AV-1 at various doses.
The BP-CATCH trial found significant racial and ethnic disparities in pediatric counseling for children with high blood pressure, but no disparities were observed among those with or without obesity. The study highlights the need to address these disparities to provide equitable care to all patients.
A phase 2 clinical trial found that a combination of two HER2 inhibitors was more effective and better tolerated than standard EGFR inhibitor-based therapy for patients with HER2-positive metastatic colorectal cancer. The study showed that the level of HER2 amplification in tumors played a key role in determining treatment outcomes.
The D-CARE study found no differences in patient behavioral symptoms or caregiver strain between health system and community-based care approaches. However, comprehensive care improved caregiver self-efficacy, which remained consistent throughout the 18-month period.
A new phase 2 clinical trial demonstrates the safety of fecal microbiota transplantation (FMT) in preventing acute graft-versus-host disease in patients undergoing allogeneic stem cell transplants. The study found that FMT helped restore microbial diversity and promote beneficial bacterial species, supporting a healthy immune system.
A new trial will test whether taking HMB can improve patients' physical function and quality of life. The BOOST study aims to recruit 124 patients with cirrhosis and measure its effects on liver disease, mental wellbeing, and physical function over 24 weeks.
Researchers have found that surgical lung volume reduction (LVRS) for advanced emphysema patients offers better outcomes than previously reported, including lower mortality rates and fewer procedure-related complications. In contrast, endobronchial valve (EBV) placement was associated with higher occurrences of complications over time.
A blood test using Signatera detected tiny fragments of tumor DNA in the blood, which showed that adding celecoxib to treatment may improve disease-free survival for patients with stage III colon cancer. The analysis found significantly improved outcomes for those taking celecoxib compared to placebo.
A blood test detecting circulating tumor DNA (ctDNA) can predict stage 3 colon cancer patients' risk of recurrence. Adding anti-inflammatory drug celecoxib to post-surgery treatment improves disease-free survival for those with positive ctDNA tests.
A phase III trial found that combining radiotherapy with cetuximab improved disease-free survival in patients with HPV-negative head and neck cancer, but not overall survival. The treatment was also associated with higher rates of acute toxicity.
Researchers call for special ethical care as neural implants improve mobility and alleviate pain for patients with neurological disorders. However, concerns over data protection, psychological privacy and hacker risks pose significant challenges to the development of these technologies.
University of Oklahoma Health Sciences is part of a new NIH program integrating clinical research into primary care practices in medically underserved areas. The program aims to increase access to vital health care and speed up the adoption of new evidence-based guidelines.
Insilico Medicine has successfully dosed the first patient in its global Phase I clinical trial of ISM6331, a potent pan-TEAD inhibitor. The treatment demonstrates superior efficacy and safety in preclinical studies, with potential synergistic anti-tumor effects and overcoming drug resistance.
A research team from the University of Minnesota Medical School received a $1.2 million grant to study the use of TMS in addition to CBIT as a treatment for children with Tourette syndrome. The trial found that this new treatment improved brain circuits involved in tics, and the researchers hope it could lead to a future treatment option.
Despite decreased aspirin use among adults with low and higher ASCVD risk, many patients with limited benefit to treatment continue taking aspirin. The study highlights the need for better understanding of individual risk factors to improve treatment decisions.
A study demonstrates the effectiveness of telephone-delivered acceptance and commitment therapy in reducing fatigue's interference with functioning and improving quality of life for metastatic breast cancer survivors. The remote intervention showed promise in reducing sleep interference, leading to improved sleep quality and a greater ...
Researchers found that short-course antibiotics can be as effective as traditional longer treatments in preventing death and recurrence of pneumonia. This approach offers significant value for healthcare systems by reducing hospital expenditure while maintaining excellent patient outcomes.
A 12-week randomized controlled trial found that IDPN using ENEFLUID increased energy intake from food and reduced hypoglycemia during dialysis, suggesting potential benefits for malnourished hemodialysis patients. However, the study did not demonstrate direct improvements in nutritional markers.
The study, published in the Journal of Clinical Oncology, showed no significant difference in patient survival between two-drug and three-drug chemotherapy regimens. The researchers found that the three-drug regimen may increase toxicity but could be a viable option for specific patients with certain types of biliary tract cancers.
The phase 3 KATHERINE clinical trial found trastuzumab emtansine to be an effective adjuvant treatment for high-risk HER2-positive breast cancer patients, reducing the risk of death or invasive disease by 46% and improving survival. The study showed consistent benefits across patient subgroups, supporting T-DM1 as a new standard of care.
A new trial has found that patients with suspected invasive bladder cancer treated with initial MRI imaging and biopsy are faster than those assessed with TURBT alone. The BladderPath trial showed a median time of 53 days from referral to correct treatment, compared to 98 days for usual care.
A large UK trial found that adding procalcitonin (PCT) to routine care did not reduce IV antibiotic use in hospitalized children. The study, part of the BATCH trial, enrolled nearly 2,000 children and tested PCT's effectiveness in guiding treatment decisions.
The ePRO monitoring system significantly improved patient-physician communication and treatment explanations, supporting patient-centered cardiovascular care. The study found that the system's implementation enhanced patient outcomes and reduced healthcare disparities.
A new tablet combining albendazole and ivermectin is safe and more effective than albendazole alone in treating Trichuris trichiura and other soil-transmitted helminths. The ALIVE clinical trial showed higher cure rates for T. trichiura, hookworms, and improved egg reduction rates compared to albendazole alone.
The project aims to improve the design of clinical trials for neurological conditions like stroke, Parkinson's disease, and vascular cognitive impairment and dementia. Community partners will facilitate academic and community partnerships for clinical trial development.
A groundbreaking UK study found that using procalcitonin (PCT) to guide treatment decisions did not reduce antibiotic duration in hospitalized children. The PCT test was safe but costlier than standard methods, and healthcare teams faced challenges integrating it into their decision-making processes.
A new AI platform, TrialTranslator, helps clinicians and patients assess individual patient benefits from clinical trials by analyzing real-world data. The study reveals that machine learning can identify groups of patients in whom randomized controlled trial results are less generalizable.
A new study aims to address pain treatment disparities by empowering Black patients with chronic pain and depression to find safe, effective approaches. The EQUIPD intervention uses individual coaching to help patients work through different non-medication treatment options.
A new type of bioengineered blood vessel demonstrated superior infection resistance and better limb preservation compared to conventional synthetic grafts. The technology has the potential to reduce amputation numbers significantly, as it can be implanted immediately and is more resistant to infection than traditional options.
A systematic literature search identified high-priority clinical actions for post-acute care, including early education, risk assessment, and mental health screening. Implementing these actions can improve the quality of care for non-hospitalized TBI patients.
Researchers are investigating a water vapor system that uses small, targeted amounts of steam to kill cancer cells in patients with intermediate-risk prostate cancer. The trial aims to explore the safety and effectiveness of this treatment as an alternative to traditional therapies, which can cause life-altering side effects.